Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BNGO

Why BioNano Genomics (BNGO) Stock Is Getting Hammered Tuesday

BioNano Genomics Inc (NASDAQ:BNGO) shares are trading sharply lower in Tuesday’s session after the company announced the pricing of a $10 million public offering.

Benzinga

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

StockNews.com

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Which Stock Do Investors Consider a Heathier Investment: Bionano Genomics (BNGO) vs. Corcept Therapeutics (CORT)

The biotech industry is poised for long-term growth supported by government initiatives and the rising prevalence of chronic illnesses. While biotech stocks Bionano Genomics (BNGO) and Corcept Therapeutics (CORT) should benefit from the industry tailwinds, let us determine which stock could be considered a healthier investment.

StockNews.com

2 Biotech Stocks You Should Buy While You Can, 1 That Investors Are Avoiding

The biotech industry is well-positioned for solid growth, thanks to the rising need for high-quality healthcare and the government's push to increase domestic biotech production and research. To that end, buying fundamentally strong biotech stocks Gilead Sciences (GILD) and Jazz Pharmaceuticals (JAZZ) could be wise. However, it could be prudent…

StockNews.com

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com

Should You Watch Bionano Genomics (BNGO) this Week?

While Bionano Genomics (BNGO) is witnessing steady revenue growth, its bottom line remains in the red. Let’s dive deeper into its key financial metrics to analyze if BNGO is worth adding to your watchlists.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Is Bionano Genomics (BNGO) a Buy or Sell this Week?

Genomic testing devices manufacturer Bionano Genomics (BNGO) is witnessing steady revenue growth. However, unfortunately, it did not translate into a bottom-line improvement. Moreover, as BNGO faces the possibility of delisting, is it worth buying now? Keep reading.

StockNews.com

Is Now the Time to Buy Bionano Genomics (BNGO)?

Biotech company Bionano Genomics (BNGO) has significant topline growth under its belt. However, its bottom line outlook is concerning. Would it be wise to invest in the stock now? Let’s look at some of its financial metrics to find out….

StockNews.com

Calling All Quality Control: Get Rid of These 3 Biotech Stocks ASAP!

High-interest rates are expected to impact the growth of the biotech industry. Therefore, fundamentally weak biotech stocks Bionano Genomics (BNGO), VBI Vaccines (VBIV), and 180 Life Sciences (ATNF) might be best avoided now. Read on….

StockNews.com

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

StockNews.com

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

StockNews.com

Is This Biotech Stock a Buy for Under $3?

Biotech company Bionano Genomics (BNGO) has beaten analysts’ top-line estimate in the third quarter. However, its cash and cash equivalents balance has declined year-over-year. Therefore, is it a buy now under $3? Read on to find out….

StockNews.com

1 Biotech Stock You Shouldn't Follow Wall Street's Bullishness On

Wall Street analysts expect Biotech stock Bionano Genomics (BNGO) to grow more than 160% in the near term. However, the stock’s fundamentals appear bleak, and the stock has lost more than 20% in 2022. Therefore, investors might avoid following Wall Street’s bullishness on this stock. Let’s find out….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Stocks to Short in May, Despite the Recent Market Sell-Off

The major market indexes have witnessed a massive sell-off recently. And this has significantly benefited short-sellers. Given the possibility of further market corrections, Lightning eMotors (ZEV), Bionano Genomics (BNGO), and QuantumScape (QS) could be ideal candidates for shorting this month, as they still look overvalued at their current price levels.

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Steve Reitmeister

508 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Jazz Pharmaceuticals plc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.